Trial Profile
A Phase 2b/3 Multi-Center, Randomized, Double-Blind, Multi-Dose, Placebo-Controlled, Parallel-Group Set of Studies to Evaluate the Efficacy and Safety of Induction and Maintenance Therapy With TD-1473 in Subjects With Moderately-to-Severely Active Ulcerative Colitis
Status:
Discontinued
Phase of Trial:
Phase II/III
Latest Information Update: 12 Sep 2023
Price :
$35
*
At a glance
- Drugs Izencitinib (Primary)
- Indications Ulcerative colitis
- Focus Registrational; Therapeutic Use
- Acronyms RHEA
- Sponsors Theravance Biopharma
- 01 Jan 2023 This trial has been discontinued in Italy, according to European Clinical Trials Database record.
- 15 Sep 2021 Status changed from active, no longer recruiting to discontinued, according to a Theravance Biopharma media release, as the company intends to significantly narrow its R&D focus on its core respiratory assets revefenacin and nezulcitinib.
- 23 Aug 2021 According to a Theravance Biopharma media release, the company plans to present study results at a scientific forum. Forthcoming ata will include results from the 16-week extended induction portion of the study and the 44-week maintenance study.